General MedicationsORALStandard

INVOKAMET XR

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Standard Dose

50MG;500MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: PRIORITY Marketing status: Prescription

Summary

Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00.

Structured Monograph

Clinical summary

Approval overview INVOKAMET XR is listed in Drugs@FDA under application 205879 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE Form and strength TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG Sponsor JANSSEN PHARMS Submission history Latest submission status date: 2024-12-18 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: PRIORITY

Interaction Notes

No interaction notes stored yet.